The Proteomics Core Facility makes advanced mass spectrometry instruments, expertise, and methods for protein analysis available to the Case Comprehensive Cancer Center (Case CCC) community. The core includes two laboratory sites, one on the Case campus and one the CCF campus, with a current total of 6000 sq. ft. of lab space. The core is directed by Dr. Mark Chance and has a total staff of approximately 20 individuals including scientists specializing in mass spectrometry, protein chemistry, instrument engineering, and bioinformatics. A total of 11 mass spectrometry systems are housed in the laboratories, including both electrospray and Maldi, and ion trap, ToF, QTof, and FTMS systems. The core was established in 1999, became a part of the Case CCC in 2003, and was expanded to its current form in 2005. The services that are offered to the Case CCC community are wide-ranging and range from a drop-off service for protein identification, to collaborative services for the detection and characterization of post-translation modifications, quantitative proteomics, and protein structural analyses to open instrument access for trained users. As a part of the Case CCC, the Proteomics Core has served a growing list of investigators. In 2005, approximately 100 investigators used the facilities, with about 40% being Case CCC members. Greater than 60% of the use was funded by the NIH. The Case CCC users come from 7 of the 9 scientific programs. All Case CCC members receive a 30% discount on the cost of services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-21
Application #
8103091
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
21
Fiscal Year
2010
Total Cost
$194,457
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Burger, Denis R; Parker, Yvonne; Guinta, Kathryn et al. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice. Biol Blood Marrow Transplant 24:260-266
Anderson, Christian E; Wang, Charlie Y; Gu, Yuning et al. (2018) Regularly incremented phase encoding - MR fingerprinting (RIPE-MRF) for enhanced motion artifact suppression in preclinical cartesian MR fingerprinting. Magn Reson Med 79:2176-2182
Tartakoff, Alan Michael; Dulce, David; Landis, Elizabeth (2018) Delayed Encounter of Parental Genomes Can Lead to Aneuploidy in Saccharomyces cerevisiae. Genetics 208:139-151
Shi, Xiaojun; Wang, Bingcheng (2018) Caught in the ""Akt"": Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF. Sci Signal 11:
Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376
Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237
Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643

Showing the most recent 10 out of 1227 publications